An observational study in Allergic Rhinitis, sponsored by Istanbul University. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-01-20.
Sponsored by Istanbul University · Observational
Our aim was to evaluate the effectiveness of subcutaneous allergen immunotherapy with the symptom scores (RSS), visual analog scale (VAS) and medication scores (MS) and the impact on quality of life with rhinoconjunctivitis quality of life questionnaire (RQLQ) in allergic rhinitis patients sensitized to different allergens. Also the development of new sensitizations and asthma during the immunotherapy were determined.
Allergic rhinitis patients sensitized to at least one common aero-allergen who completed a three or five year period of allergen immunotherapy in our outpatient clinic between 2002-2013 were enrolled in the study and patients with allergic rhinitis who received only medical treatment were chosen as the control group. Patients were separated in two groups according to sensitization patterns including pollens or house dust mites. All patients were evaluated before immunotherapy, in the first and the fifth years of treatment and two years after the treatment.
1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.
This study's planned enrollment of 120 is below the median of 141 across 172 observational studies indexed under Rhinitis.
Browse Rhinitis studies →Istanbul University is the lead sponsor of 496 studies on the registry; 79 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Allergic rhinitis patients sensitized to at least one common aero-allergen who completed a three or five year period of allergen immunotherapy in our outpatient clinic between 2002-2013 were enrolled in the study and patients with allergic rhinitis who received only medical treatment were chosen as the control group. Patients were separated in two groups according to sensitization patterns including pollens or house dust mites. All patients were evaluated before immunotherapy, in the first and the fifth years of treatment and two years after the treatment.
Exclusion Criteria:
The improvent of quality of life
Time frame: 5 years
This study is status unknown, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University